2-[1-(4-FLUOROBENZYL)-1H-BENZIMIDAZOL-2-YL]-5-(4-CHLOROBENZYLTHIO)-1,3,4-OXADIAZOLE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	LVYGIGSBYMIRRK-UHFFFAOYSA-N
Smiles	Fc1ccc(Cn2c(nc3ccccc23)c4oc(SCc5ccc(Cl)cc5)nn4)cc1
InChI	InChI=1S/C23H16ClFN4OS/c24-17-9-5-16(6-10-17)14-31-23-28-27-22(30-23)21-26-19-3-1-2-4-20(19)29(21)13-15-7-11-18(25)12-8-15/h1-12H,13-14H2

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C23H16ClFN4OS
Molecular Weight	450.92
AlogP	6.38
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	6.0
Polar Surface Area	82.04
Molecular species	NEUTRAL
Aromatic Rings	5.0
Heavy Atoms	31.0

Assay Description	Organism	Bioactivity	Reference
Antifungal activity against benzimidazole-sensitive Sclerotinia sclerotiorum SS-JSZ01 assessed as inhibition of mycelium growth after 3 days followed by 96 hr incubation in light incubator	Sclerotinia sclerotiorum	0.43 ug.mL-1
Antifungal activity against benzimidazole moderately resistant Botryotinia fuckeliana BC-JfC02 assessed as inhibition of mycelium growth after 3 days followed by 96 hr incubation in light incubator	Botryotinia fuckeliana	6.07 ug.mL-1

Cross References

Resources	Reference
ChEMBL	CHEMBL2270836
PubChem	76326893

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).